A sale process now carries the thesis
- Integer is a medical device outsource manufacturer, meaning it builds parts and finished devices for OEM customers.
- The main bull case is no longer clean growth, but a strategic review that could end in a sale or merger.
- Full-year 2026 guidance was cut again, with reported sales now expected to fall 1% to 3%.
- Electrophysiology is the key worry because customers lowered forecasts for a few products in the second half of 2026.
- If no deal happens, investors will need proof that new products can drive a 2027 recovery.
Deal hopes versus weaker demand
Integer’s stock is now more about process than pure operations. Management lowered 2026 guidance again after OEM customers cut forecasts for certain electrophysiology products. Reported sales are now expected to be down 1% to 3%, and organic sales are expected to be flat to down 1%.
The bull case is that the strategic review leads to a sale, merger, or other deal at a premium. Management said the review followed recent heightened interest from possible acquirers. That matters because a buyer may value Integer’s sticky medtech manufacturing relationships more than public investors do during a weak year.
The bear case is simple. If the review ends without a deal, the company has to stand on weaker numbers. Integer already had a 2026 headwind from three new products with lower-than-expected market adoption. The newer electrophysiology forecast cuts make it harder to trust the planned 2027 growth rebound.
Finn’s overall view is mixed, not deeply negative. Integer has real assets, long customer ties, and useful manufacturing know-how. But the near-term story has shifted from steady compounding to waiting for either a transaction or clear proof that demand has stabilized.
Sticky work for medtech OEMs
Integer makes money by designing and manufacturing medical device components and, in some cases, complete devices. Its customers are original equipment manufacturers, or OEMs, which sell the final products under their own brands.
The model can be sticky. A device can take 3 to 5 years to develop and win regulatory approval, so customers do not switch key suppliers lightly. Integer often becomes deeply tied to a product before it launches, and in some cases can be a sole-source supplier for an important component.
The company also buys small businesses that add useful capabilities. In 2025 it bought Precision Coatings, BSI Parylene, and Biocoat-related assets, adding more coating technology and services. These coatings can make devices easier to use inside the body, such as helping catheters move through blood vessels.
Where it breaks is forecast control. Integer does not own the end market demand. If a customer’s device sells slower than expected, or if an OEM changes order timing, Integer feels it quickly.
Where Integer shows up
Cardio & Vascular
This is the largest product line and includes guidewires, catheters, electrophysiology tools, neurovascular products, and parts for structural heart devices. In 2025 it grew 17%, helped by new product ramps and acquisitions.
Electrophysiology and PFA catheters
Electrophysiology, including pulsed field ablation, has been a major growth idea. It is also the current problem area, since recent customer forecast cuts hit the 2026 outlook.
Cardiac Rhythm Management
Integer supplies components used in devices that manage heart rhythm. This is a steadier market, but it is not the main source of upside today.
Neuromodulation
Integer makes components and more complete devices for customers that use electrical stimulation to treat nerve-related conditions. Emerging PMA customers generated about $125 million of 2024 sales and are expected to grow 15% to 20% per year over the next 3 to 5 years.
Coatings and surface technologies
Recent acquisitions expanded Integer’s coating services, including hydrophilic, parylene, fluoropolymer, anodic, and other surface treatments. These capabilities help make the company more useful to OEMs earlier in product design.
Other Markets
Other Markets is shrinking by design. Sales fell 27% in 2025 as Integer continued its planned exit from the Portable Medical product line.
One segment, three product lines
Integer reports as one business segment, but it gives sales by product line. The mix shown uses fiscal 2025 sales from the 2025 Form 10-K, so it does not yet reflect the full 2026 electrophysiology slowdown.
What could go wrong
Strategic review ends with no deal
High impact · Medium oddsThe main bull case is now tied to a sale or merger. If the review ends without a transaction, the stock may need to trade on weaker standalone growth. That could pressure valuation if investors lose the M&A premium.
Electrophysiology weakness lasts longer
High impact · Medium oddsManagement says recent forecast cuts are not from insourcing or supplier loss. Still, customers lowered second-half 2026 forecasts for a few electrophysiology products. If this is more than an order reset, the 2027 recovery becomes less believable.
New product adoption misses again
High impact · Medium oddsInteger’s 2026 outlook already includes a 3% to 4% sales growth headwind from three new products with weaker market adoption. Two are in electrophysiology and one is in neuromodulation. This shows how a small number of programs can move the whole company.
OEM order timing stays lumpy
Medium impact · High oddsInteger depends on customer build plans. OEMs can pull orders forward, push them out, or lower forecasts as their own inventory changes. That can make a good quarter look stronger than demand really is, or a weak quarter look worse.
Debt and capital choices limit flexibility
Medium impact · Medium oddsInteger issued 2030 convertible notes and exchanged a large part of its 2028 convertible notes. It also entered a $50 million accelerated share repurchase agreement in 2026. These moves can help manage dilution or support the stock, but they also shape cash use while the company is trying to fund growth and acquisitions.
In one breath
What does Integer Holdings do?
Integer builds medical device components and finished devices for medtech OEMs. Its products show up in areas like cardio and vascular procedures, cardiac rhythm management, neuromodulation, and electrophysiology.
Why is Integer considering a sale or merger?
In April 2026, the board started a strategic review to maximize stockholder value. Management said recent heightened interest from possible acquirers helped prompt the review.
What is the biggest issue for ITGR stock right now?
The biggest issue is the split between deal hopes and weaker fundamentals. If a sale happens, investors may get a premium. If no deal happens, the market will focus on the second 2026 guidance cut and whether the 2027 recovery is real.